Sun Pharmaceutical Industries Ltd receives U.S. FDA approval for ILUMYA in adults with active psoriatic arthritis
- Approval expands ILUMYA’s U.S. use beyond moderate-to-severe plaque psoriasis.
- Supported by Phase 3 INSPIRE-1 and INSPIRE-2 studies; no new safety signals were reported.